[Chronic pulmonary heart diseases treated by fraxiparin].
The effects of fraxiparine with hypodermic on the treatment of patients with chronic pulmonary heart diseases(CPHD) at acute phase were studied. Twenty patients were hypodermically injected with 0.4 ml fraxiparine per day for 7 days as a course. Fibrin fibrinogen degradation products (FDP and D-dimer), antithrombin III (AT-III), PaO2 and PaCO2 were detected before and after the treatment. In the therapy group, FDP and D-dimer decreased after the treatment, AT-III increased. All indexes didn't alter in the control group. Fraxiparine is effective on patients with CPHD at acute phase.